# Are the Review Standards for Regenerative Medicine Products More Lenient?

> Notes from the CDE course 'Clinical Trials of Regenerative Medicine Products: Clinical Review Considerations': the efficacy-verification requirements for cell therapy products are the same as for conventional drugs. The difference lies in risk management, from the exclusion of healthy subjects and at least one year of follow-up to the up to 15 years of long-term follow-up for gene therapy.

- Author: Paul Kuo（郭曜郎）
- Date: 2026-11-13
- Pillar: Reflections & Memory
- Tags: Regenerative Medicine, Regenerative Medicine Products Act, Cell Therapy, Cell and Gene Therapy, Clinical Trials, Pharmaceutical Regulation, Center for Drug Evaluation
- Canonical: https://paulkuo.tw/en/articles/regenerative-preparation-clinical-review/
- Language: English
- Translation: AI-translated from the zh-Hant (Traditional Chinese) original
- Original (zh-Hant): https://paulkuo.tw/articles/regenerative-preparation-clinical-review.md
- Site index for LLMs: https://paulkuo.tw/llms.txt

---

> **TL;DR:** After Taiwan's two regenerative medicine laws came into effect, the "product" pathway still follows the drug standard. Cell and gene therapies can take an accelerated pathway, but the bar for efficacy evidence has not been lowered. The review standards for cell therapy state plainly that the efficacy-verification trial requirements are the same as for conventional drugs. What is special about them lies in risk, which early-phase trials must manage through design, and which may require long-term follow-up depending on product characteristics.

From 2 p.m. to 4 p.m. on 12 November 2026, I took a course at the Center for Drug Evaluation (CDE), titled "Clinical Trials of Regenerative Medicine Products: Clinical Review Considerations." After class I received an electronic certificate of completion.

Not long after the course began, a multiple-choice question appeared on the handout: compared with traditional small-molecule or large-molecule drugs, should the clinical development pathway and clinical review standards for regenerative medicine products be faster and more lenient, require greater stringency, adopt the same standard, or be uncertain and decided case by case? The same question appeared again at the end of the handout, and you could say the entire two hours were spent answering it. Below are the key points I have organized. The facts follow the handout and publicly available regulations and review documents, and I have also recorded my own understanding.

## The Two Pathways of Taiwan's Regenerative Medicine Laws: Where Do They Differ?

From 1 January 2026, the [Regenerative Medicine Act](https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0020238) and the [Regenerative Medicine Products Act](https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0030142) took effect, and from then on regenerative medicine in Taiwan has been split into two pathways.

The first is regenerative medicine techniques. These are medical services in nature, performed by specialist physicians at medical institutions for specific patients, and governed by the Regenerative Medicine Act. The first six items in Appendix 1 of the [Regulations Governing the Management of Regenerative Medicine Techniques and Designated Products](https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0020250) are all autologous cell technique items, each with a corresponding indication, medical institution qualification, and physician training requirement. When a medical institution applies to perform these six items, it may do so without attaching a report on human trial results, while regenerative techniques beyond these six must in principle include one. In addition, for diseases that are life-threatening or seriously disabling and for which no suitable drug or medical technique is available domestically, a medical institution may apply for approval case by case under Article 22 of the Regenerative Medicine Act, without completing human trials.

The second is regenerative medicine products. These are drugs in nature, developed and manufactured by biotech and pharmaceutical companies, and governed by the Regenerative Medicine Products Act. The Act divides regenerative medicine products into four categories: gene therapy, cell therapy, tissue engineering, and combination products. To be marketed, a product must in principle pass rigorous clinical trials and obtain a drug license. For treating life-threatening or seriously disabling diseases, a conditional license may be applied for after completing Phase II clinical trials.

Both pathways have acceleration mechanisms, but with different approaches. Techniques may, under specific conditions, be exempt from completing human trials. Products may apply for a conditional license after completing Phase II clinical trials. This course was about products, and only about the two categories of cell therapy and gene therapy.

## How Do the Risks of Cell Drugs Differ from Conventional Drugs?

The handout posed a short question: does blood transfusion count as cell therapy?

My understanding is that this question can be approached using two risk-analysis concepts from the old 2014 edition of the review standards for clinical trials of cell therapy products. The first is "minimal manipulation": no in vitro cell culture, and the process does not alter the original biological characteristics of the cells, such as selecting CD34+ cells from peripheral blood and reinfusing them into the patient without culture. The second is "homologous use": the cells or tissue perform the same function in the recipient as they did in the donor. Looking at blood transfusion through these two concepts, the blood cells are not cultured, and once transfused into the recipient's blood vessels they do the same thing, so both conditions are met and the risk is relatively low. As for how transfusion is classified under regulations, that still goes back to blood-related rules.

The handout then used four publicly available clinical trials to demonstrate how risk builds up layer by layer. Autologous fat harvested and directly injected locally for breast augmentation is minimal manipulation. Autologous adipose stem cells separated in vitro and administered by intravenous infusion to treat type 2 diabetes add one more step, and the dosing changes from local injection to systemic intravenous infusion. Allogeneic adipose mesenchymal stem cells expanded in vitro and administered by intravenous infusion to treat ALS have left minimal manipulation behind through culture expansion. Autologous bone marrow mesenchymal stem cells expanded and administered intrathecally plus by intramuscular injection to treat ALS add another invasive route of administration.

The U.S. FDA's 2015 guidance on designing early-phase cell and gene therapy trials also lays out the differences between cell products and conventional drugs: living cells may transform, migrate, and develop unwanted autonomous functions. Their biological activity may persist in the body for a long time. They are immunogenic. Administration often requires invasive procedures. Yield, cell survival, and potency are all hard to control, with high variability. And the results of animal studies are harder to extrapolate to humans.

## How Do Early-Phase Clinical Trials Use Design to Contain Risk?

With so many sources of risk, the focus of early-phase trial review is subject safety. The handout's content can be grouped into a few points.

**First, establish the trial objective.** When clinical experience is limited, early-phase trials follow the drug model and focus on safety assessment. It is recommended to explore the safety and tolerability of multiple doses as far as possible, while also considering production capacity to confirm that the planned dosing method is feasible. For products with sufficient supporting human experience, the goal can be proof of concept, but when citing existing human experience, the applicant must explain how large the differences in cell source, indication, and route of administration are.

**Subjects must be patients.** Cell products may cause delayed or permanent effects, so healthy adults are not accepted for enrollment. The protocol must clearly state the disease and its severity, prior treatments received, whether there is current treatment, and how much function the target organ retains. When trial risk is high, for example when using a highly invasive route of administration or when a rare but fatal risk exists, the strength of the potential efficacy must be weighed alongside it.

**Dose and dosing interval require separate thought.** Cell products can remain active in the body for a period, and the effect often takes time to appear, so the dosing interval requires separate consideration. When clinical experience is limited or absent, the starting dose, interval, and number of administrations should be determined or estimated based on animal study data. When pretreatment and post-treatment medications such as chemotherapy are needed, the rationale for their use and the reasons for dose selection must also be explained.

**Control exposure through staggered dosing and stopping criteria.** The handout lists both within-group and between-group staggered dosing, arranged with reference to the acute and subacute adverse events observed in animal studies. As I understand it, within-group staggering means observing one subject for a period after dosing before dosing the next, and between-group staggering means reviewing safety data after one dose cohort is complete before beginning the next dose cohort. For products with high safety uncertainty, early-phase trials must also define trial stopping criteria, specifying in advance what situations across the entire trial (not a single subject), such as a certain number of unexpected deaths, would require pausing enrollment, pausing dosing, or stopping the trial, to avoid exposing more subjects to risk. The handout also recommends that a Data Monitoring Committee (DMC) or Safety Review Committee (SRC) periodically review the overall results.

**Follow up for at least one year, and write the manufacturing process into the protocol.** Post-administration safety follow-up must extend to at least one year after the last cell infusion, possibly longer depending on product characteristics, covering both expected and unexpected concerns such as infusion reactions, immunogenicity, autoimmunity, rejection, disease transmission, and new malignancies or ectopic tissue formation. Customized products also raise problems uncommon in drugs: the results of some quality tests, such as sterility testing, may not be ready before dosing, so the protocol must set out risk-handling measures and inform subjects in advance. The dosing method must take into account the time the manufacturing process requires, production capacity, and the viability window of the cells, and then be assessed for feasibility to decide whether the trial needs to be modified, for example by modifying the dose design. For products with longer manufacturing times, quality-monitoring time points must be set so that a manufacturing failure can be reported early, and it must also be confirmed that the subject's condition remains suitable for treatment during the waiting period.

From a developer's perspective, what this section reminds us of is this: the constraints of the manufacturing process get written directly into the clinical trial protocol, and the trial design has to follow the product's production capacity and shelf life.

## Why Is the Efficacy Evidence for Late-Phase Trials the Same as for Conventional Drugs?

At the stage of proving efficacy, the standard for cell therapy returns to that of conventional drugs. The 2022 edition of the Review Standards for Registration of Human Cell Therapy Products states: "The efficacy-verification trial requirements for cell therapy products are the same as for conventional drugs." Even if the mechanism of action is brand-new, this does not mean a different endpoint from existing treatments must be used to assess efficacy. If the trial design differs from that of drugs generally used to treat the disease, sufficient reasons and explanations are needed. As for safety data, the 2015 edition of the Review Standards for Registration of Human Cell Therapy Products cited in the handout states plainly that the number of subjects and the duration must at least be able to detect common adverse events, and that products expected to survive long-term in the body also require long-term patient follow-up.

The course used the U.S.-approved tumor-infiltrating lymphocyte (TIL) therapy lifileucel (brand name Amtagvi) to illustrate how this standard applies in an actual case. [The U.S. FDA granted accelerated approval on 16 February 2024](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma), with an indication for adult patients with unresectable or metastatic melanoma who had previously received PD-1 antibody treatment (and for those positive for BRAF V600 mutation, who had also used a BRAF inhibitor, with or without a MEK inhibitor). The FDA's review documents considered this patient group to have a high unmet medical need.

The pivotal trial C-144-01 was a single-arm, open-label Phase II trial. The primary efficacy endpoint was objective response rate (ORR) as assessed by an independent review committee, supported by duration of response (DoR), with the analysis methods specified in advance in the protocol. The FDA's assessment stated plainly that ORR is an intermediate endpoint reasonably likely to predict clinical benefit, and that together with DoR it was sufficient to serve as the primary efficacy basis for accelerated approval. The applicant must still complete a well-controlled randomized trial to confirm clinical benefit through progression-free survival and overall survival. As I understand it, these are the general conditions for a new cancer drug taking accelerated approval, and no discount was given because it is a cell product.

The [U.S. label](https://www.fda.gov/media/176417/download) also contains a set of numbers that show how the efficacy analysis population was derived:

> **📊 From Tumor Resection to Efficacy Analysis (C-144-01, per the U.S. Label)**
>
> - **Patients who underwent tumor resection**: 111
> - **Did not receive infusion**: 22 (19.8%), of whom 6 were because a product could not be manufactured
> - **Of the 89 who received infusion**: 2 were excluded from the efficacy analysis because the product did not meet specifications, and 5 because of product comparability issues
> - **Primary efficacy analysis population**: 82, of whom 9 received an infusion dose below 7.5×10⁹ viable cells and had no objective response
> - **The 73 in the label's efficacy table**: received an infusion dose within the approved range (7.5×10⁹ to 72×10⁹ viable cells), with an ORR of 31.5% (95% confidence interval 21.1% to 43.4%)

Of the 111 patients who underwent tumor resection, 82 ultimately entered the primary efficacy analysis. There were many reasons others did not complete the trial, of which 13 were related to product manufacturing, specifications, or comparability. For a team developing a cell drug, whether the product can be made on schedule and whether it meets specifications directly affect the number of evaluable cases, which in turn affects trial size, budget, and timeline, and must be factored in during planning.

Dose presents a similar situation. The trial's original dose range was 1×10⁹ to 150×10⁹ viable cells, with the upper limit based on published literature and the lower limit based on data from the trial's first cohort (Cohort 1). The approved dose was narrowed to 7.5×10⁹ to 72×10⁹ viable cells. The [FDA's review documents](https://www.fda.gov/media/176893/download) explain that these two figures are the lowest and highest doses received by patients who had objective responses in the pivotal cohort (Cohort 4). The same document also lists an ORR of 28.0% calculated using the 82-patient primary efficacy analysis population. According to the label, the median time from obtaining tumor tissue to completing manufacturing is 23 days, and to infusion is 34 days. Per the trial design, post-infusion assessment and survival follow-up extend to a maximum of 5 years.

## What Additional Considerations Does Gene Therapy Bring?

Gene therapy products have two approaches. One uses a vector to deliver genes directly into the patient's body. The other first removes the patient's cells, completes genetic modification in vitro, and then reinfuses them, with CAR-T belonging to the latter. Taiwan's Review Standards for Clinical Trials of Human Gene Therapy Products and Review Standards for Registration of Human Gene Therapy Products cover both categories. As I understand it, cells modified in vitro simultaneously carry cell therapy considerations, and both approaches, as long as they use a vector, require assessment of vector selection and risk. The review standards have nine clinical considerations, and the five I find most different from conventional drugs are the following.

**Pharmacokinetics adds shedding and biodistribution.** The review standards list three studies that should in principle be conducted: a shedding study, a biodistribution study, and a pharmacokinetic study of the transgene product. The shedding study looks at whether the vector will be excreted from the patient, transmitted to a third party, or enter the environment. When the vector may be excreted through semen, the contraception requirements are strengthened. Take Zolgensma, the gene therapy for spinal muscular atrophy (SMA): the [publicly available FDA review documents](https://www.fda.gov/media/127961/download) record that the trial collected saliva, urine, and stool samples at multiple time points after infusion, and that the analysis for 5 of the patients ran all the way to month 18. The design of the biodistribution study must consider cell tropism, route of administration, target organ, and vector type, while also taking into account clinical feasibility and ethical acceptability. If the transgene product is a therapeutic protein, a conventional pharmacokinetic study should in principle be conducted, including at least plasma concentration and half-life. The SMN protein expressed by Zolgensma stays inside the cell and is not secreted, so this analysis was not performed.

**For serious diseases with unmet medical need, early-phase trials ideally start from a dose that may be efficacious.** The review standards require that dose-response be assessed in principle. On this point the handout also cites the U.S. FDA's 2015 guidance on early-phase trial design, which recommends that early-phase trials explore a dose range that is biologically active or offers optimal efficacy, and generally also explore the maximum tolerated dose. The U.S. FDA's 2020 guidance on gene therapy for rare diseases mentions that for serious or life-threatening diseases with unmet medical need, early-phase trials ideally start from a dose that may be efficacious. My understanding is that first-in-human trials for conventional drugs often start from a very low dose and build up, but gene therapy vectors may trigger an immune response, and the patient may not have a chance to be dosed again, so this dose ideally has a chance to be efficacious while also having animal study support that it is sufficiently safe, which makes the range of choices very narrow. CAR-T is a different situation: CAR-T cells are expected to expand after reinfusion into the body, and within the dose range tested for Kymriah there was no clear correlation between dose and degree of expansion, so no formal dose-escalation trial was conducted.

**Immunogenicity must be looked at from both sides.** Both the vector and the transgene product may trigger an immune response. Before treatment, the patient must be assessed for pre-existing antibodies against the vector, which affects efficacy and safety and also determines whether an immunosuppressive regimen should accompany it. Zolgensma's trial monitored both anti-AAV9 antibodies and anti-SMN antibodies. On subject criteria, the handout cites the U.S. FDA's 2020 guidance on gene therapy for rare diseases: confirm the subject's pre-existing antibody status, and consider co-developing a companion diagnostic to test for pre-existing antibodies; for genetic diseases, perform genetic testing on all subjects; for pediatric patients, address ethical issues; and healthy subjects are in principle not accepted.

**Safety adds several unique categories of risk.** Besides infusion reactions and cytokine release, the review standards also require attention to infection and inflammation caused by reassortment or recombination between the vector and wild-type pathogenic strains, immune responses to the vector or transgene product, serious consequences that overexpression of the transgene may bring, malignancies that may arise from factors such as insertional mutagenesis or the transgene product itself, and unintended transduction of the vector into non-target tissues. Before and after treatment, the subject's serum and peripheral mononuclear blood samples must also be retained, so that if an unexpected infection occurs later it can be studied further.

**Long-term follow-up depends on vector characteristics.** Whether long-term follow-up is needed should be based on all available non-clinical and clinical evidence, assessing the risk of delayed adverse reactions: whether the product will edit the genome, whether it is used only for in vitro modified cells, whether expression will persist, whether it will integrate into the host genome, and whether there is a possibility of latency or reactivation. How long to follow up depends on the product and the vector. The general recommendation in the review standards is that integrating vectors reasonably warrant 15 years, gene-editing products up to 15 years, and adeno-associated virus (AAV) vectors depend on the product with a maximum of 5 years. In the first five years of a long-term follow-up plan (possibly longer depending on the product), visits must at minimum be scheduled, records kept in detail, and reporting mechanisms and detection methods established. For products subject to 15 years of follow-up, subjects must be contacted at least once a year during the subsequent ten years, and subjects previously found to have persistent vector presence must be tested once a year until it is no longer detectable.

As for efficacy, the trial design, endpoints, and control group likewise follow the guidelines of each therapeutic area. What is special is the time point of efficacy assessment and how long the efficacy can be maintained. How much flexibility the design can retain depends mainly on the characteristics of the disease. Take neurodegenerative diseases: the Guideline on Non-clinical and Clinical Development Strategies for Gene Therapy Products for Neurodegenerative Diseases notes that for a single-gene disease, if the expected efficacy is large and obvious and closely related in time to the therapeutic intervention, an innovative trial design may be considered. According to Taiwan's labels, both Zolgensma and the gene therapy for AADC deficiency were approved using single-arm trials compared against external, untreated natural history data. Other neurodegenerative diseases rely mainly on randomized, concurrently controlled trials with appropriate blinding, while innovative trial designs are also encouraged, along with early discussion with regulatory authorities.

## Back to That Multiple-Choice Question

At the end of the cell therapy section, the handout summed up in four sentences: the risk of cell therapy varies by cell type, source, manufacturing process, and manner of use; the focus of clinical review is to protect subject safety; early-phase clinical trials have high uncertainty and must manage risk through trial design; and the efficacy verification in late-phase clinical trials has the same requirements as conventional drugs. Gene therapy efficacy trials are likewise designed according to the existing guidelines of each therapeutic area, with the additional need to account for the time point of assessment and how long the efficacy can be maintained.

Looking back at that multiple-choice question with all this in mind, my answer is: efficacy verification adopts the same standard as drugs in the same therapeutic area, the trial design can retain flexibility according to disease characteristics, the safety design is handled case by case according to the product, and in areas such as the exclusion of healthy subjects and long-term follow-up, the requirements are even greater than for conventional drugs. Based on the content of this course, the option "more lenient" has no basis to be found.

What can be accelerated is the timeline; the evidence that must ultimately be delivered has not been discounted. Taiwan's conditional license follows the same logic: under the Regenerative Medicine Products Act, for products that treat life-threatening or seriously disabling diseases, that have completed Phase II clinical trials, and that are shown to be safe and to have preliminary efficacy after a risk-benefit review, a conditional license may be granted first, but with a validity period not exceeding five years and no extension after expiry. The Act also stipulates that the conditions must include conducting efficacy-verification trials and submitting trial reports periodically or within a designated period, and only after fulfilling the conditions may registration be applied for and a drug license obtained.

![Four-panel comic: Are the Review Standards for Regenerative Medicine Products More Lenient? Compared with traditional small-molecule or large-molecule drugs, should the clinical development pathway and clinical review standards for regenerative medicine products be faster and more lenient, require greater stringency, adopt the same standard, or be uncertain and decided case by case? For products that treat life-threatening or seriously disabling diseases, that have completed Phase II clinical trials, and that are shown to be safe and to have preliminary efficacy after a risk-benefit review, a conditional license may be granted first, but with a validity period not exceeding five years and no extension after expiry. The conditions must include conducting efficacy-verification trials and submitting trial reports periodically or within a designated period. The efficacy-verification trial requirements for cell therapy products are the same as for conventional drugs. What can be accelerated is the timeline; the evidence that must ultimately be delivered has not been discounted.](/images/articles/regenerative-preparation-clinical-review/01-conditional-en.svg)

This piece also goes into my regenerative medicine series. The next time I hear "regenerative medicine is faster," I will first ask: which part is faster?

> This article is my personal notes and understanding after taking the course. The facts follow the course handout and publicly available regulations and review documents, and do not represent the position of the Center for Drug Evaluation, the Ministry of Health and Welfare, or the Food and Drug Administration. On matters involving the interpretation and application of policy direction and regulations, please refer to the announcements and instructions of the health authorities.
